Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Comprehensive Overview
Published in the New England Journal of Medicine in 2019, this study asked whether a new antibody-drug conjugate could shrink tumors and delay disease progression in patients with HER2-positive metastatic breast cancer whose cancer had already worsened after an earlier antibody-drug conjugate called trastuzumab emtansine. HER2 (human epidermal growth factor receptor 2) is a protein that, when overexpressed, drives an aggressive form of breast cancer, and HER2-targeted drugs are a mainstay of treatment, but tumors eventually become resistant to the standard options. Researchers conducted a phase 2, open-label, single-group, multicenter trial testing trastuzumab deruxtecan, a drug that pairs an anti-HER2 antibody with a chemotherapy payload, delivering the toxic agent directly to cancer cells. Of 253 enrolled patients across 72 sites in eight countries, 184 women with a median of six prior lines of therapy for metastatic disease received the recommended dose, 5.4 milligrams per kilogram given intravenously every three weeks, and researchers tracked tumor shrinkage, how long responses lasted, and side effects over a median follow-up of about eleven months. The topline result was that more than 60 percent of these heavily pretreated patients responded to treatment, an unusually high rate for such a difficult-to-treat population.
Outcomes and Implications
The single most important finding was that 60.9 percent of patients had a confirmed response to trastuzumab deruxtecan, including 6.0 percent with complete disappearance of detectable tumor, and responses lasted a median of 14.8 months, with progression-free survival extending a median of 16.4 months. Nearly all patients, 97.3 percent, saw their disease controlled to some degree, and these benefits held up consistently across subgroups, including patients who had already failed the HER2-targeted drug pertuzumab and those with hormone-receptor-positive or brain-involved disease. The treatment was not without meaningful risks: nausea, fatigue, hair loss, and low blood-cell counts were common, and, more seriously, 13.6 percent of patients developed interstitial lung disease, a potentially serious inflammation and scarring of lung tissue, which contributed to four deaths and required dose adjustments, glucocorticoid treatment, or hospitalization in some cases. In a population with few remaining options after exhausting standard HER2-directed therapies, where prior third-line treatments typically produced response rates of only 9 to 31 percent, this single-arm trial demonstrated response and survival benefits that substantially exceeded those historical benchmarks, offering a meaningful new option for patients whose cancer has stopped responding to earlier antibody-based therapies. The authors concluded that trastuzumab deruxtecan showed durable antitumor activity in this heavily pretreated group, while cautioning that its risk of lung toxicity requires vigilant monitoring of pulmonary symptoms, prompt evaluation of suspected cases, and further research into which patients face the greatest risk.